Health care pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Grifols has the lowest figure of the 50 health care pharmaceutical companies ranked by P/S ratio, at 0.7, followed by Viatris (1.6) and GSK (2.2). Figures as of 20 Nov 2026, 01:52 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- Lowest
- Grifols0.7
- Median
- 6.7
- Combined market value
- ZAR 87.03T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | GrifolsGRFS · Health Care | 0.7 | ZAR 97.9B | ZAR 143.81 | 3.19% down | 0% up | ||
| 2 | ViatrisVTRS · Health Care | 1.6 | ZAR 399.7B | ZAR 348.66 | 1.97% down | 99% up | ||
| 3 | GSKGSK · Health Care | 2.2 | ZAR 1.68T | ZAR 838.67 | 1.56% down | 5% up | ||
| 4 | SanofiSNY · Health Care | 2.3 | ZAR 1.94T | ZAR 807.80 | 2.25% down | 4% down | ||
| 5 | Takeda PharmaceuticalTAK · Health Care | 2.4 | ZAR 1.2T | ZAR 375.49 | 0.66% up | 51% up | ||
| 6 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | ZAR 130.7B | ZAR 375.14 | 2.24% down | 90% up | ||
| 7 | Bristol-Myers SquibbBMY · Health Care | 2.5 | ZAR 2.09T | ZAR 1,023.17 | 2.05% down | 30% up | ||
| 8 | PfizerPFE · Health Care | 2.5 | ZAR 2.75T | ZAR 483.00 | 1.85% down | 15% up | ||
| 9 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.6 | ZAR 788.7B | ZAR 675.92 | 8.74% down | 74% up | ||
| 10 | Elanco Animal HealthELAN · Health Care | 2.8 | ZAR 230.5B | ZAR 461.08 | 1.54% down | 26% up | ||
| 11 | PTC TherapeuticsPTCT · Health Care | 2.8 | ZAR 85.5B | ZAR 1,022.91 | 3.16% down | 21% down | ||
| 12 | Legend BiotechLEGN · Health Care | 3.0 | ZAR 54.8B | ZAR 282.36 | 0.92% down | 41% down | ||
| 13 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | ZAR 216.8B | ZAR 260.09 | 1.00% down | 8% up | ||
| 14 | ZoetisZTS · Health Care | 3.5 | ZAR 575.7B | ZAR 1,416.90 | 5.59% down | 26% down | ||
| 15 | Jazz PharmaceuticalsJAZZ · Health Care | 3.6 | ZAR 266.2B | ZAR 4,146.88 | 4.57% down | 41% up | ||
| 16 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | ZAR 208.6B | ZAR 1,077.19 | 0.02% down | 17% up | ||
| 17 | Novo NordiskNVO · Health Care | 3.7 | ZAR 3T | ZAR 681.71 | 1.42% down | 17% down | ||
| 18 | Abbott LaboratoriesABT · Health Care | 4.1 | ZAR 3.16T | ZAR 1,821.68 | 0.58% down | 16% down | ||
| 19 | AstraZenecaAZN · Health Care | 4.6 | ZAR 4.77T | ZAR 3,076.36 | 1.87% down | 1% up | ||
| 20 | Ionis PharmaceuticalsIONS · Health Care | 4.8 | ZAR 79.5B | ZAR 477.39 | 0.62% down | 63% down | ||
| 21 | Merck & CoMRK · Health Care | 5.0 | ZAR 5.74T | ZAR 2,329.24 | 3.61% down | 45% up | ||
| 22 | NovartisNVS · Health Care | 5.2 | ZAR 5.01T | ZAR 2,652.11 | 2.57% down | 25% up | ||
| 23 | AlkermesALKS · Health Care | 5.3 | ZAR 136.1B | ZAR 809.91 | 1.43% down | 66% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | 5.3 | ZAR 347.2B | ZAR 2,592.48 | 1.06% down | 66% down | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 6.7 | ZAR 1.68T | ZAR 16,193.63 | 2.35% down | 28% up | ||
| 26 | Johnson & JohnsonJNJ · Health Care | 6.8 | ZAR 11.28T | ZAR 4,685.13 | 2.04% down | 34% up | ||
| 27 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | ZAR 108.2B | ZAR 765.54 | 1.25% up | 13% up | ||
| 28 | United TherapeuticsUTHR · Health Care | 7.5 | ZAR 417.6B | ZAR 9,805.55 | 3.16% down | 22% up | ||
| 29 | AbbVieABBV · Health Care | 8.2 | ZAR 8.79T | ZAR 4,972.75 | 0.86% down | 25% up | ||
| 30 | GenmabGMAB · Health Care | 8.5 | ZAR 555.3B | ZAR 900.58 | 0.75% up | 70% up | ||
| 31 | BeOne MedicinesONC · Health Care | 8.5 | ZAR 800.7B | ZAR 7,009.98 | 0.97% down | 16% up | ||
| 32 | Corcept TherapeuticsCORT · Health Care | 9.3 | ZAR 124.7B | ZAR 1,139.63 | 4.15% down | 10% down | ||
| 33 | Travere TherapeuticsTVTX · Health Care | 9.4 | ZAR 81.3B | ZAR 847.09 | 3.86% down | 45% up | ||
| 34 | Madrigal PharmaceuticalsMDGL · Health Care | 9.6 | ZAR 161.6B | ZAR 6,958.07 | 0.34% down | 27% down | ||
| 35 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 10.8 | ZAR 128.9B | ZAR 1,640.43 | 1.59% down | 129% up | ||
| 36 | Vertex PharmaceuticalsVRTX · Health Care | 11.0 | ZAR 2.32T | ZAR 9,131.39 | 2.94% down | 27% up | ||
| 37 | Axsome TherapeuticsAXSM · Health Care | 11.2 | ZAR 125.2B | ZAR 2,379.57 | 1.25% up | 6% down | ||
| 38 | Mirum PharmaceuticalsMIRM · Health Care | 12.0 | ZAR 109.4B | ZAR 1,675.06 | 3.27% up | 34% up | ||
| 39 | TG TherapeuticsTGTX · Health Care | 15.9 | ZAR 172B | ZAR 1,137.87 | 1.88% down | 117% up | ||
| 40 | Royalty PharmaRPRX · Health Care | 16.4 | ZAR 682.9B | ZAR 1,187.68 | 1.38% down | 79% up | ||
| 41 | Eli LillyLLY · Health Care | 18.5 | ZAR 21.11T | ZAR 23,696.08 | 2.29% down | 33% up | ||
| 42 | Ascendis PharmaASND · Health Care | 21.0 | ZAR 294.5B | ZAR 4,489.05 | 5.32% down | 29% up | ||
| 43 | Ligand PharmaceuticalsLGND · Health Care | 21.4 | ZAR 100.7B | ZAR 5,032.38 | 3.94% down | 50% up | ||
| 44 | BridgeBio PharmaBBIO · Health Care | 30.3 | ZAR 267.1B | ZAR 1,371.13 | 0.22% up | 21% up | ||
| 45 | Rhythm PharmaceuticalsRYTM · Health Care | 42.7 | ZAR 142B | ZAR 2,048.45 | 1.88% down | 18% up | ||
| 46 | InsmedINSM · Health Care | 52.3 | ZAR 555.8B | ZAR 2,533.55 | 20.58% up | 40% down | ||
| 47 | CytokineticsCYTK · Health Care | 81.4 | ZAR 125.7B | ZAR 902.51 | 0.27% up | 19% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | 176 | ZAR 142B | ZAR 2,175.08 | 2.47% down | 51% up | ||
| 49 | Dianthus TherapeuticsDNTH · Health Care | 2346 | ZAR 83.8B | ZAR 1,487.76 | 1.01% up | 108% up | ||
| 50 | Roivant SciencesROIV · Health Care | 3418 | ZAR 495.1B | ZAR 683.28 | 0.59% up | 91% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 17.5381 ZAR). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/S ratio?
Grifols (0.7), Viatris (1.6) and GSK (2.2) have the lowest P/S ratio of the 50 health care pharmaceutical companies ranked here as of 20 Nov 2026, 01:52 UTC.
How many health care pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 50 health care pharmaceutical companies ranked by P/S ratio have a combined market value of ZAR 87.03T as of 20 Nov 2026, 01:52 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/S ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.